Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

Learn more about:
Related Clinical Trial
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

Official Title

Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

Brief Summary

      Primary Objectives:

        1. To investigate the response rate (complete response plus partial response) of
           temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the
           central nervous system (mass only) in two strata:

             -  A. Initial diagnosis (mass)

             -  B. At relapse (mass)

        2. To determine hematologic toxicity: absolute neutrophil count (ANC), platelets and
           hemoglobin count.

      Secondary Objectives:

        1. To determine the response in other metastatic sites (non target) (orbit, bone marrow,
           bone, lung, liver and others)

        2. To determine the remission rate and time to relapse on temozolomide.

        3. To document the response of leptomeningeal metastasis (cerebrospinal fluid) to

Study Phase

Phase 2

Study Type


Primary Outcome

Response rate





Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2012

Completion Date

June 2015

Primary Completion Date

June 2015

Eligibility Criteria

        Inclusion Criteria:

          1. This study must be evaluated and confirmed by the local ethics committees and
             institutional review board of the participating institution, in accordance to the
             declaration of Helsinki. Informed consent must be administered and the parent or
             guardian must sign the document, authorized by the Ethics Committee and human subjects
             (therapy can not start if the documents are not signed).

          2. Patients less than 21 years of age with diagnosis of retinoblastoma with metastasis to
             the CNS (central nervous system) must be confirmed by an ophthalmologist and/or a
             pathologist; in conjunction with the pediatric oncologist.

          3. Metastasis to the CNS is defined as a mass in the chiasm or other site in the CNS,
             confirmed by MRI and/or


               1. At diagnosis

               2. At relapse after conventional therapy.

             It is acceptable to have other sites of metastatic disease: lymphatic, bone, bone
             marrow or others.

          4. All sites of metastasis must be measured in 3 planes, in millimeters and described in
             POND (Pediatric Oncology Network Database*)

          5. Quality of life must be 3 by Lansky and 50% by Karnofksy

          6. Hemogram: Hemoglobin of 7, ANC of 750, platelets of 75K.

          7. Chemistry: direct bilirubin less than 3.0, indirect bilirubin less than 4.0, AST less
             5x normal and ALT 5x normal, creatinine less than 1.5.

          8. Treatment must start not more than 15 days from diagnosis of metastatic

          9. Every patient with relapse or progression into the CNS must be documented with CT scan
             or MRI of the brain. Other sites of relapse may be evaluated, including bone marrow.

         10. Patients who are newly diagnosed should have not received any other chemotherapeutic
             therapy (with the exception of dexamethasone) 1 week before starting, or radiotherapy,
             4 weeks before starting.

         11. All patients to be included in this study must be presented to the principal
             investigator using Horizon Live Web-conferencing through the Cure4Kids website.
             Eligibility and target CNS sites will be determined, as well as non-target sites.

        Exclusion Criteria:

          1. Patients with metastatic to CNS with only CSF involvement are NOT ELIGIBLE.

          2. Relapse patients should have NOT received chemotherapy for 4 weeks, and no patient
             should have received nitroureas (melphalan, CCNU or mustard). No patient should have
             received radiation therapy in the previous 42 days. These patients are NOT eligible.

          3. Diagnosis of AIDS or HIV positive.

          4. Patients with disease NOT in the CNS are NOT eligible




N/A - 21 Years

Accepts Healthy Volunteers



Sandra Luna-Fineman, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Stanford University

Study Sponsor

Sandra Luna-Fineman, Principal Investigator, Stanford University

Verification Date

January 2017